Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG's Bayer HealthCare Applies for Regulatory Approval of Riociguat in United States and Europe


Monday, 11 Feb 2013 03:25am EST 

Bayer AG announced that its subsidiary Bayer HealthCare has submitted the oral investigational drug riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union. Riociguat was discovered by Bayer and represents the first member of a novel class of compounds, the stimulators of soluble guanylate cyclase (sGC). Riociguat is the first drug to demonstrate clinical efficacy in a placebo controlled phase III trial in inoperable CTEPH patients. The submission is supported by data from the two pivotal, global Phase III studies namely CHEST-1 and PATENT-1. Results of both studies were presented at the 2012 annual meeting of the American College of Chest Physicians (ACCP) in Atlanta, USA. Both Phase III studies on riociguat met their primary endpoint in exercise capacity. 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014